Phathom Pharmaceuticals (PHAT) Research & Development (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Research & Development data on file, last reported at $7.8 million in Q1 2026.

• On a quarterly basis, Research & Development fell 15.39% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $31.4 million, a 7.3% decrease from a year earlier, with the FY2025 full-year figure at $32.8 million, down 3.82% from the prior year.
• Research & Development for Q1 2026 stood at $7.8 million, up from $7.5 million in the prior quarter.
• Over the last five years, Research & Development for PHAT reached as high as $19.0 million in Q3 2022 and fell as low as $7.0 million in Q3 2025.
• Historically, Research & Development has averaged $11.5 million across 5 years, with a median of $9.4 million in 2024.
• Across the five-year window, Research & Development tumbled 42.21% in 2024 and advanced 23.05% in 2025, its largest moves.
• Year by year, Research & Development stood at $15.9 million in 2022, then slipped by 16.0% to $13.4 million in 2023, then plunged by 35.92% to $8.6 million in 2024, then decreased by 12.7% to $7.5 million in 2025, then climbed by 3.71% to $7.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $7.8 million in Q1 2026, $7.5 million in Q4 2025, and $7.0 million in Q3 2025.